Brian Nichols
Value, research analyst, author, long only

Furiex Pharma: What's The Best Plan Of Action?

In the last week, Furiex Pharmaceuticals (NASDAQ:FURX) soared 135% after its diarrhea drug proved statistically significant in two Phase 3 trials that enrolled 2,428 patients. As a result, Furiex will seek FDA approval in the next quarter, and European approval within the next year. Furiex's drug, Eluxadoline, will treat diarrhea-predominant irritable bowel syndrome (IBS-d), a disease that effects 28 million people in the U.S. and in Europe combined. Therefore, Furiex has a lot of options as it plans to market Eluxadoline: It could market alone, find a partner, or be acquired, but what's the best plan of action for investors?

Going solo or finding a partner, which is best?

There's no denying that Furiex has a lot of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details